pemvidutide — Topline data
H2 2027
The Company expects to report topline data in the second half of 2027Source filing
ALT biotech catalysts & pipeline
ALTIMMUNE INC · Data as of 2026-10-25
Upcoming catalysts
pemvidutide — Clinical data readout
2029
In August 2026, the Company announced the initiation of the global PERFORMA Phase 3 MASH trial, with 52-week data readout anticipated in 2029Source filing
pemvidutide — Conference presentation
Nov 7
Abstract Title : Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial Session : MASLD/MASH Therapeutics Date/Time : Saturday, November 7, 2026, 1 p.m. - 2 p.m. MT Presenter : Dr. Mazen NoureddinSource filing
pemvidutide — Conference presentation
Nov 7
Abstract Title : Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model Session : Industry Review Showcase Date/Time : Saturday, November 7, 2026, 8:15 a.m. MT Presenter : John J. SuschakSource filing
pemvidutide — Conference presentation
Nov 8
Abstract Title : Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis Session : Clinical Trial Pipeline for MASH 2026 Date/Time : Sunday, November 8, 2026, 11:45 a.m. – 12:00 p.m. MT Presenter : Dr. Naim AlkhouriSource filing